B+
Bull case
15%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
XCUR
ExicureFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Burixafor provides a potential clinical and strategic option, with Phase 2 completion and prior published data offering a possible long-term value path. However, no current efficacy readout, analyst target, or confirmed near-term catalyst is available.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional financing may be required in the short term, with no assurance it will be available on acceptable terms [#PR-EARNINGS-2026-03-26].
Momentum
88
Value
41
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.15 · Bull $2.10 · Bear $0.55Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum88 · Δ7d -
Value41 · Δ7d -0.0
Sentiment30 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Additional financing may be required in the short term, with no assurance it will be available on acceptable terms [#PR-EARNINGS-2026-03-26].
- • Micro-cap biotech volatility and potential equity issuance can produce severe dilution and price gaps.
- • The financing overhang, going-concern uncertainty, limited cash runway, filing-process disruption, and lack of confirmed post-earnings information outweigh the pipeline option value.
Catalyst clock
2026-08-06
Q2 2026 earnings follow-up remains unconfirmed
Lead driver: Sentiment · See AI snapshot
Momentum
88
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
30
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 87.9 / Value 41.2 / Sentiment 30.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
B
Base case
40%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$9.03M
Beta
4.11
Shares Out
6.55M
P/E (TTM) · Derived
-1.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.37
Rev YoY
-100.0%
EPS YoY
-57.6%
Gross Margin
-64.8%
Op Margin
-2365.0%
Net Debt
-$3.57M
Current Ratio
0.56
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data